GlassScriptPhysician profile
John T Presson
NPI 1629078258
$6,258.58
in general payments reported to CMS, 2019-2025
36 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $610 · 2020: $516 · 2021: $767 · 2022: $870 · 2023: $1,369 · 2024: $627 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,496.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $826.84 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $807.68 | 2021-2025 | |
| Pfizer INC. | $676.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $595.11 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $510.82 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Supernus Pharmaceuticals, INC. | $477.70 | 2019-2021 | Xyosted |
| Lilly USA, LLC | $391.44 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $275.47 | 2022-2025 | |
| Exact Sciences Corporation | $177.92 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $175.75 | 2022 | |
| Allergan, INC. | $153.50 | 2020 | |
| Phathom Pharmaceuticals, INC. | $141.13 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $126.52 | 2021 | |
| Eisai INC. | $107.67 | 2021 | |
| Corium, LLC | $106.95 | 2023 | Adlarity, Azstarys |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $83.13 | 2019 | |
| Halozyme INC | $62.86 | 2023 | |
| Dexcom, INC. | $58.71 | 2023-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $57.84 | 2021 | |
| Astellas Pharma US INC | $41.47 | 2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $40.20 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.86 | 2025 | Jardiance |
| Amgen INC. | $36.26 | 2024-2025 | Krystexxa |
| Tris Pharma INC | $36.10 | 2023-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $30.34 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $28.95 | 2024 | Gemtesa |
| Sanofi Pasteur INC. | $24.92 | 2023 | |
| Antares Pharma, INC. | $21.91 | 2024 | Xyosted |
| Mannkind Corporation | $21.84 | 2025 | |
| Lundbeck LLC | $20.80 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $20.67 | 2025 | Auvelity |
| Medtronic USA, INC. | $20.49 | 2019 | |
| Nabriva Therapeutics, Plc | $19.44 | 2022 | |
| Abbott Laboratories | $16.35 | 2025 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $13.97 | 2025 | Tirosint, Flector, Licart |
| Horizon Therapeutics Plc | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Presson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.